For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein. The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson's disease, Alzheimer's disease, and Huntington's disease.
The National Institute on Aging (NIA), part of the Federal Government's National Institutes of Health (NIH) at the U.S. Department of Health and Human Services, has primary responsibility for basic, clinical, behavioral, and social research in Alzheimer's disease (AD) as well as research aimed at finding ways to prevent and treat AD. The Institute's AD research program is integral to one of its main goals, which is to enhance the quality of life of older people by expanding knowledge about the aging brain and nervous system.
Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivaties lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's disease.
The study is published in the current issue fo the Journal of Alzheimer's Disease.
Li-Hueh Tsai became interested in the brain when she saw what happens when the mind begins to crumble. As a small child, she saw her grandmother suffer from Alzheimer's disease - an experience that left a deep impression on her and helped shape her scientific carerr. Tsai, now the director of the Picower Institute for Learning and Memory at MIT, has developed a powerful model of Alzheimer's disease using mice, and is working to better understand and stop the disease that robs people of their memories, independence, and personality.
Alzheimer's disease (AD) researchers are testing the effectiveness of gene therapy for the first time to treat patients with this common brain disease. Emory University is one of 12 institutions participating in a nationwide study to test the experimental medication, CERE-110.
The Phase 2 clinical trial seeks to enroll a total of 50 study participants with mild to moderate AD.
For the first time ever, Alzheimer's disease is a focus at the World Economic Forum. Today, more than 35 million people worldwide have dementia and those numbers will double every 20 years to 65.7 million in 2030 and 115.4 million in 2050, according to the World Alzheimer's Report from Alzheimer's Disease International (ADI), a London-based, nonprofit, international federation of 71 national Alzheimer organizations.
Drowsiness, staring off into space, or losing your train of thought may be early symptoms of Alzheimer's disease, according to a new study.
Researchers found that people with at least three different symptoms of mental lapses like these were 4.6 times more likely to have dementia than people without such episodes. In addition, people with mental lapses tended to have more severe Alzheimer's symptoms and perform worse on memory and thinking tests.
Diabetes may hasten progression to dementia in older people with mild thinking impairment, new research shows.
So-called mild cognitive impairment, or MCI, increases a person's risk of developing Alzheimer's disease and other types of dementia. But aside from a person's severity of mental impairment, there is currently no way to predict which people with MCI will go on to develop full-blown dementia.
Diabetes has been tied to mental decline and dementia in aging, but it is not currently known whether people with MCI who have diabetes are at greater risk of future dementia.